Donor-specific anti-human leukocyte antigen class I antibodies after implantation of cardiac valve allografts.

Abstract

The allospecific humoral immune response was examined in 31 patients in the first year after implantation of cryopreserved human cardiac valves. We determined the percentage antibodies against human leucocyte antigens (HLA) class I in a complement-dependent microlymphocytotoxicity test against a panel of 50 selected donors carrying most of the defined HLA-A and HLA-B specificities (panel-reactive antibodies). In blood samples taken immediately before implantation, no antibodies could be detected. Thereafter, antibodies were present in 23 of 31 (74%) patients (median panel-reactive antibodies: 57%, range 9% to 91%). In 21 patients the HLA-type of the valve donor was available. In four patients no blood samples taken after 4 weeks were available. In 14 of 17 patients (82%) with a follow-up of more than 1 month antibodies were present, and in 12 of these 14 (86%) antibodies were specifically directed against HLA class I of the donor. In conclusion, the formation of donor-specific antibodies is frequently observed after human cardiac valve replacement. It could be one of the factors leading to valve destruction and dysfunction.